血清sEGFR、CEA及Cyfra21-1水平对非小细胞肺癌患者预后的影响

doi:10.6040/j.issn.1671-7554.0.2019.691

摘要/Abstract

摘要： 目的探讨非小细胞肺癌(NSCLC)患者血清可溶性表皮生长因子受体(sEGFR)、癌胚抗原(CEA)、细胞角蛋白19片段(Cyfra21-1)表达水平与总生存期的相关性。方法选取NSCLC患者127例(病理类型为鳞癌42例、腺癌85例,TNM分期为II +III期45例、IV期82例)。采用ELISA法检测血清sEGFR表达量,电化学发光法检测血清CEA、Cyfra21-1表达量,分析上述指标表达水平正常值组与异常值组NSCLC患者的临床病理特征以及与预后之间的关系。结果 NSCLC患者的sEGFR、CEA表达水平与临床分期有关联(P<0.05)。腺癌患者血清CEA显著高于鳞癌(P<0.05),血清Cyfra21-1在患者疾病一般特征中差异无统计学意义(P>0.05)。血清sEGFR降低、CEA和Cyfra21-1水平升高的患者中位总生存期分别为9.0(4.0,21.25)、8.5(4.0,16.0)和8.0(4.0,13.25)个月,与正常值组相比差异均有统计学意义(P<0.05)。结论 NSCLC患者sEGFR表达水平降低、CEA和Cyfra21-1升高与总生存期存在明显的相关性,可通过检测患者血清sEGFR、CEA、Cyfra21-1水平评估预后。

关键词: 非小细胞肺癌, 可溶性表皮生长因子受体, 癌胚抗原, 细胞角蛋白19片段, 预后

Abstract: Objective To investigate the correlation between the expression levels of serum soluble epidermal growth factor receptor(sEGFR), carcinoembryonic antigen(CEA), cytokeratin 19 fragment(Cyfra21-1), and overall survival of patients with non-small cell lung cancer(NSCLC). Methods Altogether 127 NSCLC cases were involved, including 42 cases of squamous carcinoma and 85 cases of adenocarcinoma. The TNM stage was II+III in 45 cases and IV in 82 cases. The sEGFR expression was detected with ELISA, and CEA and cyfra21-1 levels were detected with electrochemical luminescence. The relationship between the levels of sEGFR, CEA, Cyfra21-1 and the clinicopathological characteristics and prognosis of NSCLC patients were analyzed. Results The expressions of sEGFR and CEA in NSCLC patients were correlated with the clinical stage (P<0.05). Patients with adenocarcinoma showed significantly higher CEA than patients with squamous carcinoma (P<0.05), while serum Cyfra21-1 had no statistically significant characteristics (P>0.05). The median survival of patients with reduced serum sEGFR, increased CEA, and increased Cyfra21-1 was 9.0(4.0-21.25)months, 8.5(4.0, 16.0)months and 8.0(4.0, 13.25)months, respectively, which were statistically significant compared with patients with normal expressions (P<0.05). Conclusion The decrease of sEGFR, increase of CEA and Cyfra21-1 in patients with NSCLC is significantly correlated with the overall survival, and the prognosis can be assessed by detecting the serum levels of sEGFR, CEA and Cyfra21-1. 山东大学学报 (医学版)57卷10期 -徐淑媛,等.血清sEGFR、CEA及Cyfra21-1水平对非小细胞肺癌患者预后的影响 \=-

Key words: Non-small cell lung cancer, Soluble epidermal growth factor receptor, Carcinoembryonic antigen, Cytokeratin 19 fragment, Prognosis

中图分类号:

R734.2

徐淑媛,纪全江,国丽. 血清sEGFR、CEA及Cyfra21-1水平对非小细胞肺癌患者预后的影响[J]. 山东大学学报 (医学版), 2019, 57(10): 107-111.

XU Shuyuan, JI Quanjiang, GUO Li. Effects of serum levels of sEGFR, CEA and Cyfra21-1 on the prognosis of non-small cell lung cancer patients[J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 107-111.

参考文献

[1] 仰杰, 尤青海, 孟凡亮, 等. 非小细胞肺癌miR-211表达与功能初步研究[J]. 中华肿瘤防治杂志, 2018, 25(11): 773-777. YANG Jie, YOU Qinghai, MENG Fanliang, et al. Expression and function of miR-211 in non-small cell lung cancer [J]. Chinese Journal of Cancer Prevention and Treatment, 2018, 25(11): 773-777.
[2] Ye S, Chen X, Yao Y, et al. Thioredoxin reductase as a novel and efficient plasma biomarker for the detection of non-small cell lung cancer: a Large-scale, Multicenter study [J]. Sci Rep, 2019, 9(1): 2652.
[3] 吕丽婷, 刘益飞, 刘军, 等. EHD2在非小细胞肺癌中的表达及其临床意义[J]. 实用医学杂志, 2017, 33(22): 3769-3772. LV Liting, LIU Yifei, LIU Jun, et al. EHD2 expression and clinical significance in non-small cell lung cancer [J]. The Journal of Practical Medicine, 2017, 33(22): 3769-3772.
[4] 周婉婉, 梁冰, 王效静, 等. 非小细胞肺癌患者外周血hTERT mRNA水平检测的临床意义[J]. 东南大学学报(医学版), 2017, 36(2): 217-221. ZHOU Wanwan, LIANG Bing, WANG Xiaojing, et al. The level of hTERT mRNA in peripheral blood of non-small cell lung cancer detected by real-time PCR [J]. Journal Southeast University(Medical Science Edition), 2017, 36(2): 217-221.
[5] Zhang L, Liu D, Li L, et al. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonicantigen and neuron-specific enolase in lung cancer patients [J]. BMC Cancer, 2017, 17(1): 96. doi: 10.1186/s12885-017-3070-6.
[6] Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification [J]. Chest, 2017, 151(1): 193-203.
[7] Xu CH, Yang Y, Wang YC, et al. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer [J]. Oncotarget, 2017, 8(14): 22483-22489.
[8] Shigehiro Y, Hidehito H, Kuniko SS, et al. Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer [J]. Cancer Sci, 2015,106(10): 1402-1407.
[9] Wang N, Guo H, Dong Z, et al. Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer [J]. Cancer Manage Res, 2018, 12(10): 3463-3471.
[10] Wang J, Jiang W, Zhang T, et al. Increased CYFRA 21-1, CEA and NSE are prognostic of poor outcome for locally advanced squamous cell carcinoma in lung: a nomogram and recursive partitioning risk stratificantion analysis[J]. TranslOncol, 2018, 11(4): 999-1006.
[11] Singh P, Srivastava AN, Sharma R, et al. Circulating MicroRNA-21 expression as a novel serum biomarker for oral sub-mucous fibrosis and oral squamous cell carcinoma[J]. Asian Pac JCancer Prev, 2018, 19(4): 1053-1058.
[12] He Y, Cui Y, Chang D, et al. Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma[J]. Oncotarget, 2017, 8(42): 73115-73122.
[13] Jin J, Si J, Liu Y, et al. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy[J]. Respir Res, 2018, 19(1): 197. doi: 10.1186/s12931-018-0885-x.
[14] 冯晓云, 葛琴, 陆志斌. 非小细胞肺癌患者血清miR-133b的表达水平及其临床意义探讨[J].东南大学学报(医学版), 2015, 34(6): 934-937. FENG Xiaoyun, GE Qin, LU Zhibin. Serum miR-133b levels and its relation with clinical pathological characteristics in non-small cell lung cancer patients[J]. Journal of Southeast University(Medical Science Edition), 2015, 34(6): 934-937.
[15] Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer[J]. PLoS ONE, 2016, 11(4): e0153046. doi: 10.1371/journal.pone.0153046.
[16] Liu AM, Zhu Y, Huang ZW, et al. Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13): 5802-5814.
[17] Filippo L, Massimiliano P, Cristian R, et al. Preliminary evidence on the diagnostic and molecular role of circulating soluble EGFR in non-small cell lung cancer[J]. Mol Sci, 2015, 16(8): 19612-19630.
[18] Hui R, Yang H, Tao X, et al. Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer[J]. Oncol Lett, 2019, 18(4): 4167-4175.
[19] Romero-Ventosa EY, Blanco-Prieto S, González-Pi(~overn)eiro AL, et al. Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients [J]. Springer Plus, 2015, 9(4): 171. doi: 10.1186/s40064-015-0891-0. eCollection 2015.
[20] Dai L, Qu Y, Li J, et al. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer [J]. Oncotarget, 2017, 8(22): 36664-36673.
[21] Dal Bello MG, Filiberti RA, Alama A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer(NSCLC)patients [J]. J Transl Med, 2019, 17(1): 74. doi: 10.1186/s12967-019-1828-0.
[22] Mauro C, Passerini R, Spaggiari L, et al. New and old biomarkers in the differential diagnosis of lung cancer: pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1 [J]. Int J Biol Markers, 2019, 34(2):163-167.
[23] Wang XB, Li J, Han Y. Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a metaanalysis[J]. Tumor Biol, 2014, 35(10): 10105-10110.
[24] Baek AR, Seo HJ, Lee JH, et al. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer [J]. Cancer Biomarker, 2018, 22(1): 55-62.
[25] Parka SY, Leea JG, Kimb J, et al. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung [J]. Lung Cancer, 2013, 79(2): 156-160.

相关文章 15

[1]	郑苏,陈述花,李华,邓劼,陈春红,王晓慧,冯卫星,韩萧迪,张雨佳,李娜,李莫,方方. 脑电变化和BASED评分与54例婴儿痉挛症促肾上腺皮质激素疗效的相关性[J]. 山东大学学报 (医学版), 2022, 60(9): 91-96.
[2]	王丽慧,高敏,孔北华. 子宫血管肉瘤2例报告并文献复习[J]. 山东大学学报 (医学版), 2022, 60(9): 108-112.
[3]	高中霞,张铭,樊明德,谭晨阳,王梦迪,王超,樊跃飞,丁守銮,王成伟. 伽玛刀治疗81例肺癌脑转移瘤的疗效及预后因素[J]. 山东大学学报 (医学版), 2022, 60(8): 44-49.
[4]	贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43.
[5]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[6]	张玉凤,徐敏,邢秀丽,逄曙光,户克庆. 689例非ST段抬高型心肌梗死患者的临床流行病学特征[J]. 山东大学学报 (医学版), 2022, 60(7): 118-122.
[7]	李琳琳,王凯. 基于生物信息学预测肝细胞癌预后基因[J]. 山东大学学报 (医学版), 2022, 60(5): 50-58.
[8]	陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.
[9]	郑昊天,王光辉,赵小刚,王亚东,曾榆凯,杜贾军. 基于数据库LKB1突变肺腺癌DNA异常甲基化位点构建的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(3): 51-58.
[10]	陈立晓,英信江,陈歆维,王菲,孙臻峰,董频. 下咽鳞癌蛋白质谱鉴定及预后靶分子筛选[J]. 山东大学学报 (医学版), 2021, 59(9): 140-147.
[11]	褚晏,刘端瑞,朱文帅,樊荣,马晓丽,汪运山,郏雁飞. DNA甲基化转移酶在胃癌中的表达及其临床意义[J]. 山东大学学报 (医学版), 2021, 59(7): 1-9.
[12]	陈丽宇,肖娟,吕仙忠,段宝敏,洪凡真. 影响孕产妇下肢深静脉血栓预后的危险因素分析[J]. 山东大学学报 (医学版), 2021, 59(7): 38-42.
[13]	田瑶天,王宝,李叶琴,王滕,田力文,韩波,王翠艳. 基于可解释性心脏磁共振参数的机器学习模型预测儿童心肌炎的预后[J]. 山东大学学报 (医学版), 2021, 59(7): 43-49.
[14]	李皖皖,周文凯,董书晴,贺士卿,刘钊,张家新,刘斌. 利用数据库信息构建乳腺癌免疫关联lncRNAs风险评估模型[J]. 山东大学学报 (医学版), 2021, 59(7): 74-84.
[15]	米琦,史爽,李娟,李培龙,杜鲁涛,王传新. 膀胱癌circRNAs介导的ceRNA网络及预后评估模型的构建[J]. 山东大学学报 (医学版), 2021, 59(6): 94-102.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed